Verona Pharma (VRNA) to Release Quarterly Earnings on Thursday

Verona Pharma (NASDAQ:VRNA) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. On average, analysts expect Verona Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verona Pharma Trading Down 4.7 %

Shares of NASDAQ:VRNA opened at $14.95 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 33.33 and a current ratio of 33.33. The firm has a fifty day moving average price of $16.16 and a 200 day moving average price of $16.20. Verona Pharma has a fifty-two week low of $11.83 and a fifty-two week high of $23.81.

Insider Buying and Selling

In other Verona Pharma news, insider Kathleen A. Rickard sold 36,248 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total transaction of $71,046.08. Following the transaction, the insider now directly owns 2,621,552 shares in the company, valued at approximately $5,138,241.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Verona Pharma in a research note on Monday, March 4th. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Verona Pharma in a research report on Friday, March 1st. Finally, Piper Sandler lifted their price target on Verona Pharma from $31.00 to $36.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 16th. Four investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $33.60.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.